Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 3
2008 1
2009 1
2010 2
2011 2
2012 3
2013 3
2014 1
2016 1
2017 2
2018 1
2019 3
2020 2
2021 4
2022 2
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, Paneesha S, Fox CP, Eyre TA, Forconi F, Elmusharaf N, Kennedy B, Gribben J, Pemberton N, Sheehy O, Preston G, Schuh A, Walewska R, Duley L, Howard D, Hockaday A, Jackson S, Greatorex N, Girvan S, Bell S, Brown JM, Webster N, Dalal S, de Tute R, Rawstron A, Patten PEM, Hillmen P; National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup. Munir T, et al. Among authors: pemberton n. N Engl J Med. 2024 Jan 25;390(4):326-337. doi: 10.1056/NEJMoa2310063. Epub 2023 Dec 10. N Engl J Med. 2024. PMID: 38078508 Clinical Trial.
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, Walewska R, Furtado M, Preston G, Neilson JR, Pemberton N, Sidra G, Morley N, Cwynarski K, Schuh A, Forconi F, Elmusharaf N, Paneesha S, Fox CP, Howard DR, Hockaday A, Brown JM, Cairns DA, Jackson S, Greatorex N, Webster N, Shingles J, Dalal S, Patten PEM, Allsup D, Rawstron A, Munir T. Hillmen P, et al. Among authors: pemberton n. Lancet Oncol. 2023 May;24(5):535-552. doi: 10.1016/S1470-2045(23)00144-4. Lancet Oncol. 2023. PMID: 37142374 Free article. Clinical Trial.
Introducing 'Forensic cultures'.
Burney I, Kirby DA, Pemberton N. Burney I, et al. Among authors: pemberton n. Stud Hist Philos Biol Biomed Sci. 2013 Mar;44(1):1-3. doi: 10.1016/j.shpsc.2012.09.012. Epub 2012 Oct 22. Stud Hist Philos Biol Biomed Sci. 2013. PMID: 23085369 No abstract available.
Humanity's Best Friend: A Dog-Centric Approach to Addressing Global Challenges.
Sykes N, Beirne P, Horowitz A, Jones I, Kalof L, Karlsson E, King T, Litwak H, McDonald RA, Murphy LJ, Pemberton N, Promislow D, Rowan A, Stahl PW, Tehrani J, Tourigny E, Wynne CDL, Strauss E, Larson G. Sykes N, et al. Among authors: pemberton n. Animals (Basel). 2020 Mar 17;10(3):502. doi: 10.3390/ani10030502. Animals (Basel). 2020. PMID: 32192138 Free PMC article. Review.
Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma.
Perry MWD, Björhall K, Bold P, Brűlls M, Börjesson U, Carlsson J, Chang HA, Chen Y, Eriksson A, Fihn BM, Fransson R, Fredlund L, Ge H, Huang H, Karabelas K, Lamm Bergström E, Lever S, Lindmark H, Mogemark M, Nikitidis A, Palmgren AP, Pemberton N, Petersen J, Rodrigo Blomqvist M, Smith RW, Thomas MJ, Ullah V, Tyrchan C, Wennberg T, Westin Eriksson A, Yang W, Zhao S, Öster L. Perry MWD, et al. Among authors: pemberton n. J Med Chem. 2021 Jun 24;64(12):8053-8075. doi: 10.1021/acs.jmedchem.1c00434. Epub 2021 Jun 3. J Med Chem. 2021. PMID: 34080862
Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.
Ripa L, Sandmark J, Hughes G, Shamovsky I, Gunnarsson A, Johansson J, Llinas A, Collins M, Jung B, Novén A, Pemberton N, Mogemark M, Xiong Y, Li Q, Tångefjord S, Ek M, Åstrand A. Ripa L, et al. Among authors: pemberton n. J Med Chem. 2023 Oct 26;66(20):14188-14207. doi: 10.1021/acs.jmedchem.3c01269. Epub 2023 Oct 5. J Med Chem. 2023. PMID: 37797307
Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
Munir T, Emmerson J, Hockaday A, Oughton JB, Howard D, Phillips D, Neilson J, Pemberton N, Paneesha S, Kennedy B, Rawstron A, Hillmen P. Munir T, et al. Among authors: pemberton n. Br J Haematol. 2022 Dec;199(5):707-719. doi: 10.1111/bjh.18427. Epub 2022 Aug 26. Br J Haematol. 2022. PMID: 36017875 Free PMC article. Clinical Trial.
A class of highly selective inhibitors bind to an active state of PI3Kγ.
Gangadhara G, Dahl G, Bohnacker T, Rae R, Gunnarsson J, Blaho S, Öster L, Lindmark H, Karabelas K, Pemberton N, Tyrchan C, Mogemark M, Wymann MP, Williams RL, Perry MWD, Papavoine T, Petersen J. Gangadhara G, et al. Among authors: pemberton n. Nat Chem Biol. 2019 Apr;15(4):348-357. doi: 10.1038/s41589-018-0215-0. Epub 2019 Feb 4. Nat Chem Biol. 2019. PMID: 30718815
36 results